This company listing is no longer active
ELN Stock Overview
Elanix Biotechnologies AG, a tissue regeneration company, engages in the development and commercialization of products for acute wound care.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Elanix Biotechnologies AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.053 |
| 52 Week High | €0.20 |
| 52 Week Low | €0.0005 |
| Beta | 0 |
| 1 Month Change | 6.00% |
| 3 Month Change | -37.65% |
| 1 Year Change | -64.67% |
| 3 Year Change | -94.75% |
| 5 Year Change | -98.20% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.7% | -1.2% | 1.7% |
| 1Y | -64.7% | -23.0% | 2.3% |
Return vs Industry: ELN underperformed the German Biotechs industry which returned -5.5% over the past year.
Return vs Market: ELN underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| ELN volatility | |
|---|---|
| ELN Average Weekly Movement | 3,131.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ELN's share price has been volatile over the past 3 months.
Volatility Over Time: ELN's weekly volatility has increased from 1714% to 3131% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Lee-Ann Laurent-Applegate | www.elanixbiotechnologies.ch |
Elanix Biotechnologies AG, a tissue regeneration company, engages in the development and commercialization of products for acute wound care. The company is based in Frankfurt am Main, Germany.
Elanix Biotechnologies AG Fundamentals Summary
| ELN fundamental statistics | |
|---|---|
| Market cap | €428.29k |
| Earnings (TTM) | -€4.46m |
| Revenue (TTM) | €280.19k |
0.0x
P/S Ratio0.0x
P/E RatioIs ELN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELN income statement (TTM) | |
|---|---|
| Revenue | €280.19k |
| Cost of Revenue | €348.59k |
| Gross Profit | -€68.39k |
| Other Expenses | €4.39m |
| Earnings | -€4.46m |
Last Reported Earnings
Jun 30, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ELN perform over the long term?
See historical performance and comparison